CN101035755B - 脱保护的方法 - Google Patents

脱保护的方法 Download PDF

Info

Publication number
CN101035755B
CN101035755B CN2005800338074A CN200580033807A CN101035755B CN 101035755 B CN101035755 B CN 101035755B CN 2005800338074 A CN2005800338074 A CN 2005800338074A CN 200580033807 A CN200580033807 A CN 200580033807A CN 101035755 B CN101035755 B CN 101035755B
Authority
CN
China
Prior art keywords
protected
acid
deprotection
method described
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800338074A
Other languages
English (en)
Chinese (zh)
Other versions
CN101035755A (zh
Inventor
J·格里格
N·奥斯博恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CN101035755A publication Critical patent/CN101035755A/zh
Application granted granted Critical
Publication of CN101035755B publication Critical patent/CN101035755B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
CN2005800338074A 2004-10-05 2005-09-23 脱保护的方法 Expired - Fee Related CN101035755B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0422004.2 2004-10-05
GBGB0422004.2A GB0422004D0 (en) 2004-10-05 2004-10-05 Method of deprotection
PCT/GB2005/003692 WO2006037950A1 (en) 2004-10-05 2005-09-23 Method of deprotection

Publications (2)

Publication Number Publication Date
CN101035755A CN101035755A (zh) 2007-09-12
CN101035755B true CN101035755B (zh) 2011-12-21

Family

ID=33428035

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800338074A Expired - Fee Related CN101035755B (zh) 2004-10-05 2005-09-23 脱保护的方法

Country Status (6)

Country Link
US (1) US7714115B2 (https=)
EP (1) EP1797029A1 (https=)
JP (1) JP5000521B2 (https=)
CN (1) CN101035755B (https=)
GB (1) GB0422004D0 (https=)
WO (1) WO2006037950A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070260267A1 (en) * 2002-10-07 2007-11-08 Nicoson Zachary R Localizing obturator
PT2106808T (pt) * 2006-12-21 2018-03-26 Nihon Mediphysics Co Ltd Agente de imagiologia de diagnóstico radioativo compreendendo ácido 1-amino-3-[18f]fluoro-ciclobutanocarboxílico
BRPI0720465B8 (pt) 2006-12-27 2021-07-27 Nihon Mediphysics Co Ltd processo para produção de composto de precursor para composto orgânico marcado com halogênio radioativo
JP5258583B2 (ja) * 2007-02-13 2013-08-07 日本メジフィジックス株式会社 放射性画像診断剤の製造方法
EP2005970A1 (de) 2007-06-22 2008-12-24 Berlin Science Partners GmbH i.V. Bildgebende Diagnostik durch Kombination von Kontrastmitteln
US8043316B2 (en) 2008-05-02 2011-10-25 Suros Surgical Systems, Inc. Adjustable spacer
GB0905515D0 (en) * 2009-03-31 2009-05-13 Ge Healthcare Ltd Radiolabelling methods
JP2013510891A (ja) * 2009-11-17 2013-03-28 バイエル・ファルマ・アクチェンゲゼルシャフト Ｆ−１８標識のグルタミン酸誘導体の製造法
WO2011157443A1 (en) * 2010-06-17 2011-12-22 N.V. Organon (11b,17a)-11-(4-(2-11c-acetyl)phenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one
AU2011351550B2 (en) * 2010-12-29 2017-02-02 Ge Healthcare Limited Eluent solution
US9101895B2 (en) 2011-04-15 2015-08-11 General Electric Company System for mixing and dispersing microbubble pharmaceuticals
KR101221483B1 (ko) * 2011-05-13 2013-01-16 서강대학교산학협력단 Ｆ-18 표지 방사성의약품 합성 장치 및 방법
US11534494B2 (en) 2011-12-21 2022-12-27 Ge Healthcare Limited Formulation and method of synthesis
GB201411569D0 (en) 2014-06-30 2014-08-13 Ge Healthcare Ltd Novel formulation and method of synthesis
CN109966515A (zh) * 2011-12-21 2019-07-05 通用电气健康护理有限公司 在柠檬酸盐缓冲液中的18F-Fluciclovine组合物
US10473668B2 (en) * 2014-06-06 2019-11-12 The Regents Of The University Of California Self-shielded, benchtop radio chemistry system with a plurality shielded carriers containing a disposable chip cassette
DK3481804T3 (da) 2016-06-10 2025-01-13 Univ Johns Hopkins Forbedret syntese af radioaktivt mærket hæmmer af prostataspecifikt membranantigen (PSMA) [18F]DCFPyL
EP3551232B1 (en) * 2016-12-07 2022-03-23 Università degli Studi di Bari "Aldo Moro" Stable f-dopa formulations and uses thereof
WO2018235535A1 (ja) * 2017-06-23 2018-12-27 日本メジフィジックス株式会社 放射性ハロゲン標識化合物の製造方法および放射性医薬の製造方法
JPWO2022196734A1 (https=) * 2021-03-17 2022-09-22

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135683A (en) * 1991-03-28 1992-08-04 Arco Chemical Technology, L.P. Process for producing a deprotected alkoxylated polyol
US5393908A (en) 1992-06-25 1995-02-28 Satyamurthy; Nagichettiar Synthesis of N-formyl-3,4-di-t-butoxycarbonyloxy-6-(trimethylstannyl)-L-phenylalanine ethyl ester and its regioselective radiofluorodestannylation to 6-[18 F]fluoro-L-dopa
DE4330889C2 (de) * 1993-09-11 2002-10-31 Emtec Magnetics Gmbh Verfahren zur Wiedergewinnung von Rohmaterialien aus magnetischen Aufzeichnungsträgern
US5922810A (en) * 1995-07-31 1999-07-13 Fmc Corporation Deprotection of protected functional polymers
BE1010280A3 (fr) * 1996-05-02 1998-05-05 Coincidence S A Procede et dispositif de synthese de 2-[18f] fluoro-2-deoxy-d-glucose.
DE10104250A1 (de) * 2001-01-31 2002-08-14 Deutsches Krebsforsch Markierungsfähige Verbindungen zur einfachen Synthese von 3'-[18F]Fluor-3'-deoxythymidin und Verfahren zu deren Herstellung
EP1356827A1 (en) * 2002-04-24 2003-10-29 Mallinckrodt Inc. Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution
US7022872B2 (en) * 2003-12-19 2006-04-04 Molecular Technologies, Inc. Method for making fluorine labeled L-Dopa

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Bryan Li 等.Aqueous phosphoric acid as a mild reagent fordeprotection of the t-butoxycarbonyl group,8113-8115.Tetrahedron Letters44 44.2003,44(44),表一. *
BryanLi等.Aqueousphosphoricacidasamildreagentfordeprotectionofthet-butoxycarbonylgroup 8113-8115.Tetrahedron Letters44 44.2003
K. Hamacher等.Efficient Stereospecific Synthesis of No-Carrier-Added 2-[18F]-Fluoro-2-Deoxy-D-Glucose Using AminopolyetherSupported Nucleophilic Substitution,235-238.J. Nucl. Med.27 2.1986,34(2),全文.
K. Hamacher等.Efficient Stereospecific Synthesis of No-Carrier-Added 2-[18F]-Fluoro-2-Deoxy-D-Glucose Using AminopolyetherSupported Nucleophilic Substitution,235-238.J. Nucl. Med.27 2.1986,34(2),全文. *
WO 94/00460 A1,全文.
Yu Shin Ding等.Synthesis of high specific activity 6-[18F] fluorodopaminefor positron emission tomography studies ofsympathetic nervous tissue,861-863.J. Med. Chem.34 2.1991,34(2),全文.
Yu Shin Ding等.Synthesis of high specific activity 6-[18F] fluorodopaminefor positron emission tomography studies ofsympathetic nervous tissue,861-863.J. Med. Chem.34 2.1991,34(2),全文. *

Also Published As

Publication number Publication date
US20080076914A1 (en) 2008-03-27
EP1797029A1 (en) 2007-06-20
WO2006037950A1 (en) 2006-04-13
JP5000521B2 (ja) 2012-08-15
GB0422004D0 (en) 2004-11-03
US7714115B2 (en) 2010-05-11
CN101035755A (zh) 2007-09-12
JP2008515793A (ja) 2008-05-15

Similar Documents

Publication Publication Date Title
CN101035755B (zh) 脱保护的方法
Bianchi et al. Traceless staudinger ligation of glycosyl azides with triaryl phosphines: Stereoselective synthesis of glycosyl amides
EP3663307A1 (en) Production method for radiolabeled aryl compound
EP3329775A1 (en) Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
HRP20120154T1 (hr) HETEROCIKLIČKI INHIBITORI MEK-a I METODE NJIHOVE UPORABE
EP2128130B1 (en) Process for production of precursor compound for radioactive halogen-labeled organic compound
CN105503872A (zh) 一种利格列汀杂质及其制备方法和应用
CN104762666A (zh) 双重运行盒
Petersen et al. A new, efficient glycosylation method for oligosaccharide synthesis under neutral conditions: preparation and use of new DISAL donors
US9650410B2 (en) Process for the preparation of abiraterone and abiraterone acetate
CN106478597A (zh) 富马酸沃诺拉赞单晶及其制备方法和用途
Sun et al. Pre-activation based, highly alpha-selective O-sialylation with N-acetyl-5-N, 4-O-carbonyl-protected p-tolyl thiosialoside donor
Patel et al. Flow chemistry kinetic studies reveal reaction conditions for ready access to unsymmetrical trehalose analogues
EP1742922B1 (en) Crystalline pyrazole derivative
CN101560190B (zh) 缬沙坦中杂质e的研究及控制方法
EP2327395A1 (en) Process for the preparation of gadobenate dimeglumine complex in a solid form
CN101735164A (zh) 缬沙坦中杂质f的研究及控制方法
CN109810065A (zh) 一种恶拉戈利的合成方法
CN110437275A (zh) 一种促进脑功能化合物甘磷酸胆碱的合成方法
CN101492419B (zh) 氨溴索盐
Hengeveld et al. Facile N-demethylation of erythromycins
EP2646411B1 (en) Preparation of pet precursor
KR101904565B1 (ko) 1-아미노-3-히드록시-시클로부탄-1-카르복실산 유도체의 제조
CN105085405A (zh) 4-[1-甲基-5-(2-氯乙基-2-羟乙基)胺基-2-苯并咪唑基]丁酸盐酸盐的制备方法与应用
HK40111817A (en) Production method for radiolabeled aryl compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111221

Termination date: 20150923

EXPY Termination of patent right or utility model